By continuing to use this site, you consent to our use of cookies to personalize your experience and to analyze website traffic. Learn more in our Privacy Policy.

Accept
Privacy Policy

See results of a survey of people who tube feed conducted by Alcresta and the Oley Foundation #

#

Real experiences with RELiZORB

RELiZORB (iMMOBILIZED lipase) cartridge

See how patients like Caleb use RELiZORB

Learn how actual patients use RELiZORB in their tube-feeding routines and how it might benefit you

Caleb, a child who tube feeds with RELiZORB, and his mom, Kayleigh

Video thumbnail of Caleb and his mother, Kayleigh, sharing their experience with using RELiZORB

Caleb’s story

Meet Caleb, a 6-year-old with short bowel syndrome, and his mother, Kayleigh, and hear about their experience

Video thumbnail for 'Caleb's Story,' showing Caleb with his mom and his doctor working together as a team.

Caleb’s story: collaborative care

Learn how important it was for Caleb and Kayleigh to build a strong connection with their treating clinician, Dr. Sivan Kinberg

See how RELiZORB is helping a 17-year-old student and lacrosse player living with cystic fibrosis

Trenton’s story

See how RELiZORB is helping a 17-year-old student and lacrosse player living with cystic fibrosis

Answering questions about day-to-day life and how RELiZORB has helped with tube feeding

Mary’s story

Answering questions about day-to-day life and how RELiZORB has helped with tube feeding

Discussing cystic fibrosis, tube feeding, and RELiZORB

Mariah’s story

Discussing cystic fibrosis, tube feeding, and RELiZORB

Previous generation RELiZORB may be used in patient videos.

We made more progress on Caleb’s nutritional status in the 2 months after starting RELiZORB than we had the previous 5 months before we started.

— Kayleigh, mom to Caleb, who tube feeds with RELiZORB

RELiZORB is indicated for use in pediatric (including neonates and infants) and adult patients to hydrolyze fats during enteral feeding.

Warnings
  • RELiZORB is for use with enteral tube feeding only.
See more
#

RELiZORB is indicated for use in pediatric (including neonates and infants) and adult patients to hydrolyze fats during enteral feeding.

Warnings
  • RELiZORB is for use with enteral tube feeding only.
  • RELiZORB should not be connected to any intravenous (IV) line, setup, or system.
  • Medications should not be administered through the RELiZORB cartridge. Do not add medications to the enteral nutrition or tubing before RELiZORB. The passage of medications through RELiZORB may adversely affect the medications or the ability of RELiZORB to hydrolyze fats.
  • Fibrosing Colonopathy - Fibrosing colonopathy is a rare, serious adverse reaction associated with high-dose use of pancreatic enzyme replacement therapy in the treatment of patients with cystic fibrosis. The underlying mechanism of fibrosing colonopathy remains unknown. Patients with fibrosing colonopathy should be closely monitored because some patients may be at risk of progressing to stricture formation. RELiZORB contains lipase enzyme that is not from a porcine source. The lipase is bound to the beads, and this lipase-bead complex (iLipase) is retained within the RELiZORB cartridge. Continue to follow your physician’s guidance and porcine pancreatic enzyme labeling regarding porcine pancreatic enzyme use when used in conjunction with RELiZORB.
Cautions and Precautions
  • Do not re-use RELiZORB. RELiZORB is a single-use product. Re-use may result in contamination of the product. If re-used, RELiZORB may not effectively hydrolyze fats.
  • Do not break, alter, or place excess pressure on any part of RELiZORB. Any compromise of the structural integrity of RELiZORB may lead to improper connection to enteral feeding supplies, leakage or risk of contamination.
  • Do not use RELiZORB after the date marked on the pouch.
  • Enteral nutrition administered through RELiZORB is for immediate consumption through an enteral feeding tube. RELiZORB should not be used to process enteral nutrition for later use. This has not been tested and may result in safety issues.
  • RELiZORB is designed for use with enteral feeding pump systems with low flow/no flow alarms and enteral syringes for manual bolus by syringe (push or gravity). A detailed listing of enteral nutrition, pumps, and enteral feeding supplies compatible with RELiZORB can be found at www.relizorb.com/compatibility.
  • Patients less than 1 year old may be particularly vulnerable to unplanned interruptions of feeding.
  • Do not use blenderized formulas with RELiZORB. A detailed listing of enteral nutrition compatible with RELiZORB can be found at www.relizorb.com/compatibility.
  • Powdered formulas should be mixed periodically during feedings.
  • Do not use excessive force on the plunger when using RELiZORB with bolus syringe feeding method.
  • Do not rush bolus feeds. Follow guidance from your healthcare professional on how long it should take you to complete your tube feeding. Ensure all inlet and outlet connectors on RELiZORB and enteral feeding supplies are clean and dry prior to making connections.
  • In order to ensure product performance, store RELiZORB in its pouch either refrigerated or at room temperature (2°C to 27°C; 36°F to 80°F).
  • RELiZORB is indicated for use with enteral feeding only; patients should follow physician’s guidance for pancreatic enzyme replacement therapy (PERT) use for meals and snacks. Patients and patient caregivers should follow physician’s guidance regarding the need for pancreatic enzyme replacement therapy (PERT) during enteral feeding.

Review full product information for RELiZORB in the Instructions for Use.